Abstract | BACKGROUND: METHODS: We enrolled patients with head and neck cancer who were treated with induction chemotherapy between September 2014 and March 2016. In this double-blind trial, patients were randomly assigned to the TJ-14 group or placebo group. Patients were instructed to dissolve 2.5 g of TJ-14 or placebo in 100 ml of drinking water, rinse their mouths with the solution for 30 s and then spit it out. They were not allowed to eat anything for 30 minutes before or after using the mouthwash. RESULTS: The incidence of ≥ grade 2 OM was 37.5% (three patients) in the TJ-14 group and 50.0% (four patients) in the placebo group, with no significant difference between the two groups. The mean day of onset was 9.7 in the TJ-14 group and 6.7 in the placebo group. The mean duration of ≥ grade 2 OM was 1.3 days in the TJ-14 group and 3.7 days in the placebo group. Thus TJ-14 significantly reduced the duration of ≥ grade 2 OM. CONCLUSION: Treatment of OM with TJ-14 was associated with a statistically significant reduction in the duration of ≥ grade 2 OM compared to placebo. Gargling with TJ-14 is a safe and effective method of administering the drug to patients with head and neck cancer.
|
Authors | Kenkichiro Taira, Kazunori Fujiwara, Takahiro Fukuhara, Satoshi Koyama, Hiromi Takeuchi |
Journal | Yonago acta medica
(Yonago Acta Med)
Vol. 63
Issue 3
Pg. 183-187
(Aug 2020)
ISSN: 0513-5710 [Print] Japan |
PMID | 32884437
(Publication Type: Journal Article)
|
Copyright | ©2020 Tottori University Medical Press. |